title: Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2.
abstract: BACKGROUND
  The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of interleukin-2 (IL-2) in patients with non-muscle-invasive bladder carcinoma. In addition, this study aimed to determine the significance of immune parameters for recurrence-free interval.
  
  
  METHODS
  Twenty-six patients with non-muscle-invasive bladder carcinoma were treated with intravesical instillations of IL-2 (Proleukin®, Novartis, formerly Chiron) in doses of 9 × 10(6) IU on 5 consecutive days, beginning on the second day after transurethral resection (TUR) of tumours. CD8(high)CD57(+) lymphocytes in peripheral blood were determined before TUR and compared with the recurrence-free interval after treatment.
  
  
  RESULTS
  The multivariate analysis showed that CD8(high)CD57(+) lymphocytes had a prognostic significance in combination with number of bladder tumours, prior recurrence rate and age of patients.
  
  
  CONCLUSIONS
  Peripheral blood CD8(high)CD57(+) lymphocytes have prognostic significance for recurrence-free survival in patients with non-muscle-invasive bladder carcinoma after TUR and intravesical IL-2.
authors.affiliation: Faculty of Medicine, Vilnius University, MKČiurlionio 21, LT-03101 Vilnius, Lithuania. dainius.characiejus@gmail.com
authors.forename: Dainius
authors.initials: D
authors.lastname: Characiejus
authors.forename: Vita
authors.initials: V
authors.lastname: Pasukoniene
authors.forename: John J L
authors.initials: JJ
authors.lastname: Jacobs
authors.forename: Rimantas
authors.initials: R
authors.lastname: Eidukevicius
authors.forename: Feliksas
authors.initials: F
authors.lastname: Jankevicius
authors.forename: Neringa
authors.initials: N
authors.lastname: Dobrovolskiene
authors.forename: Mykolas
authors.initials: M
authors.lastname: Mauricas
authors.forename: R Jeroen A
authors.initials: RJ
authors.lastname: Van Moorselaar
authors.forename: Willem
authors.initials: W
authors.lastname: Den Otter
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018959:CD57 Antigens / Q000096:biosynthesis / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000601:surgery
chemical_list: D018959:CD57 Antigens; D007376:Interleukin-2